Pulse Biosciences Q3 2025 revenue $86k, GAAP net loss ($19.4M), cash $95.2M

PULSE BIOSCIENCES, INC.

Revenue of $86k from limited market release of nPulse Vybrance system.
GAAP net loss ($19.4M) vs ($12.7M) in Q3 2024; Non-GAAP net loss ($13.5M) vs ($9.4M).
Cash $95.2M at Sep 30, 2025; operating cash burn $13.0M in Q3 2025.
Enrolled 40% of subjects in PRECISE-BTN thyroid nodule study; FDA IDE approved for NANOCLAMP AF surgical trial.
Treated 150 patients with nsPFA 360° catheter in European AF feasibility study; IDE submission filed.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.